Successful treatment for prostate cancer tested at Houston Methodist Hospital


“We strategically used an adenovirus, similar to the one that causes the common cold, to carry the therapy agent, a herpes virus gene that produces the enzyme thymidine kinase, or TK, directly into the tumor cells,” said E. Brian Butler, M.D., chair of the Department of Radiation Oncology at Houston Methodist. He also revealed that a vaccine with the patient’s own cells was created and used at the same time. Prostate biopsies performed at 24 months after completion of treatment were negative in 83 percent The results were reported in the JRO paper. “This is extremely pleasing to us, considering we had patients enrolled in our protocol after other physicians deemed them incurable,” said Bin Teh, M.D., vice chair of Houston Methodist’s Department of Radiation Oncology and lead author on the JRO paper.


Please enter your comment!
Please enter your name here